arrow
D

Deborah T. Blumenthal

Tel Aviv University
H指数:43
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2,异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者中,体素(3D)评估相较于传统双向(2D)评估在INDIGO III期试验中的比较

2025-11-010
OAAI
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率(TGR)建模预测了在INDIGO三期试验中,接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者的临床结局。

2025-11-010
OAAI
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

Vorasidenib在IDH1突变或IDH2突变低级别胶质瘤(INDIGO):一项随机、双盲、安慰剂对照、III期试验的次要和探索性终点

2025-10-290
PRE
EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

早期肿瘤体积变化预测Midh1/2胶质瘤的临床结局:INDIGO III期试验的事后分析结果

2025-10-010
OAAI
EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB

来自INDIGO研究第3阶段的探索性分析表明,在VORASIDENIB治疗下,通过肿瘤体积减小可能存在控制癫痫发作的潜在机制。

2025-10-010
OA
A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
2024-11-110
PRE
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
2024-08-113
OAAI
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium

联合免疫疗法可改善Anti-PD-1单一疗法失败的复制修复缺陷 (RRD) 高级别神经胶质瘤的结果: 来自国际RRD联盟的报告

2023-10-1212
OAAI
INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION
2023-09-080
OA
Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Glioma
2023-08-17227
OA
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption
2023-08-074
OAAI
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival following Immunotherapy in Murine GBM.
2023-04-250
PRE
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
2022-06-283
OAAI
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

生殖系DNA复制修复缺陷儿童对PD-1抑制反应的基因组预测因子

2022-01-0672
OAAI
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825

独立验证的性别特异性列线图可预测新诊断的胶质母细胞瘤患者的生存率: NRG肿瘤学RTOG 0525和0825

2021-11-1014
OA